Found: 53
Select item for more details and to access through your institution.
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2014, v. 14, n. 3, p. 169, doi. 10.1016/j.clbc.2013.10.016
- By:
- Publication type:
- Article
Activated Ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00167
- By:
- Publication type:
- Article
Adnectin-Targeted Inhibitors: Rationale and Results.
- Published in:
- Current Oncology Reports, 2015, v. 17, n. 8, p. 1, doi. 10.1007/s11912-015-0459-8
- By:
- Publication type:
- Article
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 53, doi. 10.1007/s10549-020-05817-w
- By:
- Publication type:
- Article
Targeted therapy for sarcomas.
- Published in:
- Biologics: Targets & Therapy, 2014, v. 8, p. 91, doi. 10.2147/BTT.S26555
- By:
- Publication type:
- Article
Apoptosis: mechanisms and implications for cancer therapeutics.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 197, doi. 10.1007/s11523-006-0034-1
- By:
- Publication type:
- Article
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 2, p. 284, doi. 10.1007/s10637-023-01342-x
- By:
- Publication type:
- Article
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3
- By:
- Publication type:
- Article
Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 341, doi. 10.1007/s10637-014-0183-5
- By:
- Publication type:
- Article
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1236, doi. 10.1007/s10637-014-0145-y
- By:
- Publication type:
- Article
The role of mTOR inhibitors for treatment of sarcomas.
- Published in:
- Current Oncology Reports, 2007, v. 9, n. 4, p. 316, doi. 10.1007/s11912-007-0039-7
- By:
- Publication type:
- Article
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.
- Published in:
- Cancers, 2018, v. 10, n. 6, p. 160, doi. 10.3390/cancers10060160
- By:
- Publication type:
- Article
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 974, doi. 10.1007/s10637-013-9930-2
- By:
- Publication type:
- Article
Metabolism of patupilone in patients with advanced solid tumor malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 605, doi. 10.1007/s10637-012-9838-2
- By:
- Publication type:
- Article
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1065, doi. 10.1007/s10637-011-9642-4
- By:
- Publication type:
- Article
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 4, p. 359, doi. 10.1007/s10637-006-9031-6
- By:
- Publication type:
- Article
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 4, p. 357, doi. 10.1007/s10637-007-9047-6
- By:
- Publication type:
- Article
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0221994
- By:
- Publication type:
- Article
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Published in:
- Journal of Cellular & Molecular Medicine, 2010, v. 14, n. 10, p. 2448, doi. 10.1111/j.1582-4934.2009.00832.x
- By:
- Publication type:
- Article
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 4, p. 701, doi. 10.1007/s00280-015-2682-2
- By:
- Publication type:
- Article
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 6, p. 1113, doi. 10.1007/s00280-014-2572-z
- By:
- Publication type:
- Article
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
- Published in:
- 2014
- By:
- Publication type:
- Report
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 193, doi. 10.1007/s00280-012-1996-6
- By:
- Publication type:
- Article
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 35, doi. 10.1007/s00280-012-1963-2
- By:
- Publication type:
- Article
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
- Published in:
- 2012
- By:
- Publication type:
- Report
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
- Published in:
- 2012
- By:
- Publication type:
- Report
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 2, p. 287, doi. 10.1007/s00280-008-0869-5
- By:
- Publication type:
- Article
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
- By:
- Publication type:
- Article
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0
- By:
- Publication type:
- Article
Bromodomain inhibitors a decade later: a promise unfulfilled?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Bromodomain inhibitors a decade later: a promise unfulfilled?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
- Published in:
- Molecular Carcinogenesis, 2024, v. 63, n. 8, p. 1421, doi. 10.1002/mc.23738
- By:
- Publication type:
- Article
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00360-5
- By:
- Publication type:
- Article
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 10463, doi. 10.2147/CMAR.S208720
- By:
- Publication type:
- Article
Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
PARP Inhibition in Cancer: An Update on Clinical Development.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 73, doi. 10.1007/s11523-013-0267-8
- By:
- Publication type:
- Article
Are we ready to move away from nature?: the rapamycin story.
- Published in:
- 2011
- By:
- Publication type:
- journal article
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
- Published in:
- 2011
- By:
- Publication type:
- journal article
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
- Published in:
- 2009
- By:
- Publication type:
- journal article